134 related articles for article (PubMed ID: 9353388)
1. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
[TBL] [Abstract][Full Text] [Related]
2. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
3. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype.
Numa AM; Abbott FS; Chang TK
Can J Physiol Pharmacol; 2007 Sep; 85(9):848-55. PubMed ID: 18066130
[TBL] [Abstract][Full Text] [Related]
4. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
Amini-Shirazi N; Ghahremani MH; Ahmadkhaniha R; Mandegary A; Dadgar A; Abdollahi M; Shadnia S; Pakdaman H; Kebriaeezadeh A
Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621
[TBL] [Abstract][Full Text] [Related]
6. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
[TBL] [Abstract][Full Text] [Related]
7. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
8. CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid.
Rettie AE; Sheffels PR; Korzekwa KR; Gonzalez FJ; Philpot RM; Baillie TA
Biochemistry; 1995 Jun; 34(24):7889-95. PubMed ID: 7794900
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
[TBL] [Abstract][Full Text] [Related]
10. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
Levy RH; Rettenmeier AW; Anderson GD; Wilensky AJ; Friel PN; Baillie TA; Acheampong A; Tor J; Guyot M; Loiseau P
Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
Ho PC; Abbott FS; Zanger UM; Chang TK
Pharmacogenomics J; 2003; 3(6):335-42. PubMed ID: 14597963
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
Kassahun K; Baillie TA
Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
[TBL] [Abstract][Full Text] [Related]
13. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
Tang W; Borel AG; Fujimiya T; Abbott FS
Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
15. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
Bello M; Mendieta-Wejebe JE; Correa-Basurto J
Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
[TBL] [Abstract][Full Text] [Related]
16. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes.
Jurima-Romet M; Abbott FS; Tang W; Huang HS; Whitehouse LW
Toxicology; 1996 Aug; 112(1):69-85. PubMed ID: 8792850
[TBL] [Abstract][Full Text] [Related]
18. P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of Delta 3-valproic acid generated by baculovirus-expressed CYP3A1.
Fisher MB; Thompson SJ; Ribeiro V; Lechner MC; Rettie AE
Arch Biochem Biophys; 1998 Aug; 356(1):63-70. PubMed ID: 9681992
[TBL] [Abstract][Full Text] [Related]
19. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
[TBL] [Abstract][Full Text] [Related]
20. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
